Marshall Wace, LLP Verve Therapeutics, Inc. Transaction History

Marshall Wace, LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$13.34 - $19.9 $683,474 - $1.02 Million	51,235 New	51,235 $960,000
Q2 2022 Aug 15, 2022	BUY	$11.14 - $23.17 $562,558 - $1.17 Million	50,499 New	50,499 $772,000
Q1 2022 May 16, 2022	SELL	$20.92 - $39.36 $19,643 - $36,959	-939 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$31.94 - $54.82 $29,991 - $51,475	939 New	939 $35,000

182

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $456M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.